文献速递类风湿关节炎

改善病情抗风湿药预防或延缓类风湿关节炎发病的能力:系统文献综述与荟萃分析

Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.
PubMed 文献 · Ann Rheum Dis · 2018-06-08

该系统综述与荟萃分析纳入2006至2016年发表的10项试验报告、共1156例患者,评估改善病情抗风湿药或糖皮质激素预防或延缓类风湿关节炎发病的疗效。在无关节炎的关节痛人群中,两项研究的荟萃分析未显示52周及以上时类风湿关节炎发生率显著降低(合并OR 0.74,95%CI 0.37至1.49);在未分化关节炎人群中,七项研究的荟萃分析显示风险显著降低(OR 0.73,95%CI 0.56至0.97)。结论认为早期治疗干预可能显著降低疾病最初阶段的类风湿关节炎发病风险。

要点

  • 在无关节炎的关节痛(类风湿关节炎风险)人群中,合并OR 0.74(95%CI 0.37至1.49),未达统计学显著。
  • 在未分化关节炎人群中,合并OR 0.73(95%CI 0.56至0.97),风险显著降低。
  • 共纳入10项试验报告、1156例患者,平均症状持续时间16.2±12.6周。

核心结论

  • 该荟萃分析表明早期治疗干预可能显著降低疾病最初阶段的类风湿关节炎发病风险。

研究设计与样本

  • 系统文献综述与荟萃分析,检索PubMed、EMBASE和Cochrane数据库2006至2016年发表的英文文献,关键词为「未分化关节炎」或「极早期类风湿关节炎」联合「治疗」。
  • 纳入改善病情抗风湿药或糖皮质激素用于具有类风湿关节炎遗传和/或环境风险因素和/或类风湿关节炎相关系统性自身免疫和/或无临床关节炎的症状和/或未分化关节炎患者的随机对照试验报告。
  • 共筛选595篇摘要,纳入10项试验报告,包括1156例患者,平均症状持续时间16.2±12.6周。
  • 主要结局为类风湿关节炎发生,定义为符合1987年ACR标准;荟萃分析采用RevMan软件及Mantel-Haenszel法。

主要发现

  • 9项研究报告了类风湿关节炎发生情况,评估的药物包括甲泼尼龙、甲氨蝶呤、一种肿瘤坏死因子阻断剂、阿巴西普或利妥昔单抗。
  • 在无关节炎的关节痛(类风湿关节炎风险)人群中,两项研究的荟萃分析未显示52周及以上时类风湿关节炎发生率显著降低(合并OR 0.74,95%CI 0.37至1.49)。
  • 在未分化关节炎人群中,七项研究的荟萃分析显示风险显著降低(OR 0.73,95%CI 0.56至0.97)。

关键数值与推荐

  • 无关节炎的关节痛(类风湿关节炎风险)人群:合并OR 0.74(95%CI 0.37至1.49),未达统计学显著。
  • 未分化关节炎人群:合并OR 0.73(95%CI 0.56至0.97),达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention. OBJECTIVES: To assess the efficacy of therapeutic interventions in preventing or delaying RA onset with a systematic literature review (SLR) and meta-analysis (MA). METHODS: The SLR aimed to include all reports of randomised controlled trials of disease-modifying antirheumatic drugs or glucocorticoids used in patients presenting genetic and/or environmental risk factors for RA and/or systemic autoimmunity associated with RA, and/or symptoms without clinical arthritis and/or unclassified arthritis and in patients with RA. We searched PubMed, EMBASE and Cochrane databases for English articles published from 2006 to 2016 using the keywords 'undifferentiated arthritis' or 'very early rheumatoid arthritis' with 'therapy' or 'treatment'. Main outcome was RA occurrence, defined as fulfilment of the 1987 ACR criteria. The MA was performed with RevMan with the Mantel-Haenszel method. RESULTS: Among 595 abstracts screened, 10 reports of trials were selected. The studies included 1156 patients, with mean symptom duration 16.2±12.6 weeks. The occurrence of RA was available for nine studies, assessing methylprednisolone, methotrexate, a tumour necrosis factor blocker, abatacept or rituximab. In the group arthralgia without arthritis (people at risk of RA), the MA of the two available studies did not show significant reduction in RA occurrence at week 52 or more (pooled OR 0.74, 95% CI 0.37 to 1.49). For people with undifferentiated arthritis, the MA of the seven available studies revealed significant risk reduction with OR 0.73(95% CI 0.56 to 0.97). CONCLUSIONS: This MA demonstrates that early therapeutic intervention may significantly reduce the risk of RA onset in this very first phase of the disease.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hilliquin S, Hugues B, Mitrovic S, et al. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. Ann Rheum Dis. 2018. PMID: 29884751. doi:10.1136/annrheumdis-2017-212612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。